DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2003/0104601 A1 Deangelis (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2003/0104601 A1 Deangelis (43) Pub US 20030104601A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0104601 A1 DeAngelis (43) Pub. Date: Jun. 5, 2003 (54) CHONDROITINSYNTHASE GENE AND Publication Classification METHODS OF MAKING AND USING SAME (51) Int. Cl." ............................ C12P 21/02; C12N 1/21; (76) Inventor: Paul L. DeAngelis, Edmond, OK (US) C07H 21/04; CO8B 37/00; C12N 9/24; C12N 15/74; Correspondence Address: C12O 1/68 DUNLAP, CODDING & ROGERS PC. (52) U.S. Cl. ..................... 435/200; 435/69.1; 435/320.1; PO BOX 16370 435/252.3; 536/23.2; 536/54; OKLAHOMA CITY, OK 73114 (US) 435/6 (21) Appl. No.: 09/842,484 (57) ABSTRACT (22) Filed: Apr. 25, 2001 Related U.S. Application Data The present invention relates to a chondroitin Synthase gene and methods of making and using Same. In more particular, (63) Continuation-in-part of application No. 09/283,402, but not by way of limitation, the present invention relates to filed on Apr. 1, 1999, now abandoned, and which is a a chondroitin Synthase gene from Pasteurella multocida and continuation-in-part of application No. 09/437.277, methods of isolating and using Same. Additionally, the filed on Nov. 10, 1999, now Pat. No. 6,444447. present invention relates to the use of unsulfated chondroitin and its preparation, as well as conversion into modified (60) Provisional application No. 60/199,538, filed on Apr. versions Such as dermatan Sulfate and chondroitin Sulfate 25, 2000. polymers. Patent Application Publication Jun. 5, 2003. Sheet 5 of 10 US 2003/0104601 A1 Std CS V HAS 2. S . w y - as Y 8 as is a s sis s O A4 C - - - 12 14 16 18 20 22 Time (min) Fig. 3 Patent Application Publication US 2003/0104601 A1 r bib a vil ?t Patent Application Publication Jun. 5, 2003. Sheet 7 of 10 US 2003/0104601 A1 DEANGELIS STD. SNMOL 10/15/00 Standard 1000 800 600 400 200 O 10.0 20.0 30.0 40.0 50.0 60.0 SAMPLEF REPEAT 5NMOL. 10/15 Pasteurella 1000 Chondroitin 800 600 400 200 O 0 200 300 40.0 50.0 60.0 Patent Application Publication Jun. 5, 2003 Sheet 8 of 10 US 2003/0104601 A1 100 75 É 50 25 9 10 11 12 13 14 5 6 Time (min) Fig. 6 200 150 É 100 50 Time (min) Fig. 7 Patent Application Publication Jun. 5, 2003 Sheet 9 of 10 US 2003/0104601 A1 NMR of Typc F Polymer HOD 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm Fig. 8 Patent Application Publication Jun. 5, 2003. Sheet 10 of 10 US 2003/0104601 A1 ABCase Treatment 0.012 0.010 0.008 0.006 e 0.004 0.002 O.OOO ADiOS -0.002 -0.004 25 50 75 100 minutes Fig. 9 ACase Treatment 0.012 0.010 0.008 t (). OO6 0.004 ADiOS OOO2 0.000 5() 75 minutes Fig. 10 US 2003/0104601 A1 Jun. 5, 2003 CHONIDROITN SYNTHASE GENE AND a GAG intermediate. Also GAGS may sequester or bind METHODS OF MAKING AND USING SAME certain proteins (e.g. growth or coagulation factors) to cell Surfaces. CROSS-REFERENCE TO RELATED 0008 Certain pathogenic bacteria produce an extracellu APPLICATIONS lar polysaccharide coating, called a capsule, which Serves as 0001. This application is related to U.S. provisional a virulence factor. In a few cases, the capsule is composed application Serial No. 60/199,538 filed Apr. 25, 2000 and of GAG or GAG-like polymers. As the microbial polysac entitled “POLYMER FORMATION AND RECOGNITION charide is identical or very similar to the host GAG, the MECHANISMS AND METHODS OF MAKING AND antibody response is either very limited or non-existent. The USING SAME'; is a continuation-in-part of pending U.S. capsule is thought to assist in the evasion of host defenses patent application Ser. No. 09/283,402, filed Apr. 4, 1999 Such as phagocytosis and complement. Examples of this and entitled “DNA ENCODING HYALURONAN SYN clever Strategy of molecular camouflage are the production THASE FROM PASTEURELLA MULTOCIDA AND of an authentic HA polysaccharide by Gram-negative Type METHODS OF USE"; and is a continuation-in-part of A Pasteurella multocida and Gram-positive Group A and C pending U.S. patent application Ser. No. 09/437,277, filed StreptococcuS. The HA capsule of these microbes increases Nov. 10, 1999 and entitled “POLYMER GRAFTING BY virulence by 10° to 10-fold as measured by LDsovalues, the POLYSACCHARIDE SYNTHASES. number of colony forming units that will kill 50% of the test animals after bacterial challenge. STATEMENT REGARDING FEDERALLY 0009. The invasiveness and pathogenicity of certain E. FUNDED RESEARCH coli Strains has also been attributed to their polysaccharide 0002 The government owns certain rights in the present capsules. Two Escherichia coli capsular types, K4 and K5, invention pursuant to a grant from the National Institutes of make polymers composed of GAG-like polymers. The E. Health (GM56497) and a grant from the National Science coli K4 polymer is an unsulfated chondroitin backbone Foundation (MCB-9876193). decorated with fructose side-branches on the C3 position of the GlcUA residues. The K5 capsular material is a polysac BACKGROUND OF THE INVENTION charide, called heparosan, identical to mammalian heparin except that the bacterial polymer is unsulfated and there is 0003) 1. Field of the Invention no epimerization of GlcUA to iduronic acid. 0004. The present invention relates to a chondroitin syn 0010. The studies of GAG biosynthesis have been instru thase gene and methods of making and using Same. In more mental in understanding polysaccharide production in gen particular, but not by way of limitation, the present invention eral. The HA synthases were the first GAG glycosyltrans relates to a chondroitin Synthase gene from Pasteurella ferases to be identified at the molecular level. These multocida and methods of isolating and using Same. Addi enzymes utilize UDP-Sugar nucleotide Substrates to produce tionally, the present invention relates to the use of unsulfated large polymers containing thousands of disaccharide chondroitin and its preparation, as well as conversion into repeats. The genes encoding bacterial, Vertebrate, and viral modified versions Such as dermatan Sulfate and chondroitin HAS enzymes have been cloned. In all these cases, expres Sulfate polymers. Sion studies demonstrated that transformation with DNA 0005 2. Background Information Relating to the Inven encoding a single HAS polypeptide conferred the ability of tion foreign hosts to Synthesize HA. Except for the most recent HAS to be identified, P. multocida pmHAS, these proteins 0006 Glycosaminoglycans GAGs are long linear have similar amino acid Sequences and predicted topology in polysaccharides consisting of disaccharide repeats that con the membrane. Two classes of HASs have been proposed to tain an amino Sugar and are found in most animals. Chon exist based on these structural differences as well as poten droitin B(1, 4)GlcUA-B(1, 3)GalNAc), heparin/heparan tial differences in reaction mechanism C.1 4)GlcUA-B(1, 4)GlcNAc, and hyaluronan IB(1, 4)GlcUA-B(1, 3)GlcNAc) are the three most prevalent 0011. The biochemical study of chondroitin biosynthesis GAGS found in humans. Chondroitin and heparin typically in vertebrates was initiated in the 1960s. Only recently have have n=20 to 100, while hyaluronan typically has n=10. the mammalian enzymes for elongation of the polysaccha Chondroitin and heparin are Synthesized as glycoproteins ride backbone of chondroitin been tentatively identified by and are Sulfated at various positions in vertebrates. Hyalu biochemical means. An 80-kDa GlcUA transferase found in roman is not Sulfated in Vertebrates. A Substantial fraction of vertebrate cartilage and liver was implicated in the biosyn the GlcUA residues of heparin and chondroitin are epimer thesis of the chondroitin backbone by photoaffinity labeling ized to form iduronic acid. with an azidoUDP-GlcUA probe. A preparation from bovine 0007 Many lower animals possess these same GAGs or serum with the appropriate GalNAc- and GlcUA-transferase very Similar molecules. GAGS play both Structural and activities in vitro was obtained by conventional chromatog recognition roles on the cell Surface and in the extracellular raphy, but Several bands on SDS polyacrylamide gels matrix. By virtue of their physical characteristics, namely a (including a few migrating ~80 kDa) were observed. high negative charge density and a multitude of polar 0012 Chondroitin polysaccharide (beta-1,3-GalNAc hydroxyl groups, GAGS help hydrate and expand tissues. beta-1,4-GlcUA); n=~10-2000) has use as a hyaluronan Numerous proteins bind selectively to one or more of the (HA) polysaccharide Substitute in medical or cosmetic appli GAGs. Thus the proteins found on cell surfaces or the cations. Both chondroitin and hyaluronan form Viscoelastic associated extracellular matrices (e.g. CD44, collagen, gels (Suitable for eye or joint applications) or hydrophilic, fibronectin) of different cell types may adhere or interact via hygroscopic materials (Suitable for moisturizer or wound US 2003/0104601 A1 Jun. 5, 2003 dressings). Unmodified or underivatized chondroitin is not multocida and methods of isolating and using Same. Addi known to exist or, if present, in Very Small quantities in the tionally, the present invention relates to the use of unsulfated human body. The main advantage is that byproducts of chondroitin and its preparation, as well as conversion into natural HA degradation (by shear, enzyme, radical or oxi modified versions Such as dermatan Sulfate and chondroitin dation processes) have certain biological activities with Sulfate polymers. respect to Vascularization, angiogenesis, cancer, tissue modulation, but similar byproducts of chondroitin (in the BRIEF DESCRIPTION OF THE SEVERAL proposed unsulfated, unmodified State) may not have the VIEWS OF THE DRAWINGS Same biological activity.
Load more

Recommended publications
  • Phd Thesis Tjaard Pijning
    University of Groningen Divergent or just different Rozeboom, Henriette IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2014 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Rozeboom, H. (2014). Divergent or just different: Structural studies on six different enzymes. [S.n.]. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne- amendment. Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 29-09-2021 Divergent or just different Structural studies on six different enzymes Henriëtte Rozeboom Printed by Ipskamp Drukkers, Enschede The research presented in this thesis was carried out in the Protein Crystallography group at the Groningen Biomolecular Sciences and Biotechnology Institute.
    [Show full text]
  • The Crystal Structure of Novel Chondroitin Lyase ODV-E66, A
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector FEBS Letters 587 (2013) 3943–3948 journal homepage: www.FEBSLetters.org The crystal structure of novel chondroitin lyase ODV-E66, a baculovirus envelope protein ⇑ Yoshirou Kawaguchi a, Nobuo Sugiura b, Koji Kimata c, Makoto Kimura a,d, Yoshimitsu Kakuta a,d, a Laboratory of Structural Biology, Graduate School of System Life Sciences, Kyushu University, 6-10-1 Hakozaki, Fukuoka 812-8581, Japan b Institute for Molecular Science of Medicine, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi 480-1195, Japan c Research Complex for the Medicine Frontiers, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi 480-1195, Japan d Faculty of Agriculture, Kyushu University, 6-10-1 Hakozaki, Fukuoka 812-8581, Japan article info abstract Article history: Chondroitin lyases have been known as pathogenic bacterial enzymes that degrade chondroitin. Received 5 August 2013 Recently, baculovirus envelope protein ODV-E66 was identified as the first reported viral chondroi- Revised 1 October 2013 tin lyase. ODV-E66 has low sequence identity with bacterial lyases at <12%, and unique characteris- Accepted 15 October 2013 tics reflecting the life cycle of baculovirus. To understand ODV-E66’s structural basis, the crystal Available online 26 October 2013 structure was determined and it was found that the structural fold resembled that of polysaccharide Edited by Christian Griesinger lyase 8 proteins and that the catalytic residues were also conserved. This structure enabled discus- sion of the unique substrate specificity and the stability of ODV-E66 as well as the host specificity of baculovirus.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,569,386 B2 Deangelis (45) Date of Patent: Aug
    US007569386B2 (12) United States Patent (10) Patent No.: US 7,569,386 B2 DeAngelis (45) Date of Patent: Aug. 4, 2009 (54) CHONDROITINSYNTHASE GENE AND Terminal Position of Chondroitin Sulfate’ Nakanishi et al. The Jour METHODS OF MAKING AND USING SAME nal of Biological Chemistry 1981, 256 (11) 5443-5449). “Differences in the Effects of pH on the Hydrolytic and (75) Inventor: Paul L. DeAngelis, Edmond, OK (US) Transgalactosylic Reactions of Beta-Galactosidase (Escherichia coli), Huber et al., Can. J. Biochem. Cell Biol. 61: 198-206 (1983). (73) Assignee: The Board of Regents of the University “Binding and Reactivity at the 'Glucose' Site of Galactosyl-Beta Galactosidase (Escherichia coli), Huber et al., Arch Biochem of Oklahoma, Norman, OK (US) Biophys. 234: 151-160 (1984). (*) Notice: Subject to any disclaimer, the term of this “Effect of Replacing Uridine 33 in Yeast tRNAPhe on the Reaction patent is extended or adjusted under 35 With Ribosomes”. Dix et al., J. Biol. Chem., 261(22): 101 12-8 (1986). U.S.C. 154(b) by 656 days. "Structure and Serological Characteristics of the Capsular K4 Anti gen of Escherichia coli O5:K4:H4, A Fructose-Containing Polysac (21) Appl. No.: 11/042,530 charide With a Chondroitin Backbone', Rodriguez et al., Eur, J. Biochem., 177:117-124 (1988). (22) Filed: Jan. 24, 2005 “The Carboxy-Terminal Domain of the LexA Repressor Oligomerises Essentially as the Entire Protein'. Schnarret al., FEBS (65) Prior Publication Data Lett. 234:56-60 (1988). US 2005/O164984 A1 Jul. 28, 2005 "A Cryptic Fimbrial Gene in Serratia Marcescens”. Moriya et al., J.
    [Show full text]
  • X-Ray Fluorescence Analysis Method Röntgenfluoreszenz-Analyseverfahren Procédé D’Analyse Par Rayons X Fluorescents
    (19) & (11) EP 2 084 519 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: G01N 23/223 (2006.01) G01T 1/36 (2006.01) 01.08.2012 Bulletin 2012/31 C12Q 1/00 (2006.01) (21) Application number: 07874491.9 (86) International application number: PCT/US2007/021888 (22) Date of filing: 10.10.2007 (87) International publication number: WO 2008/127291 (23.10.2008 Gazette 2008/43) (54) X-RAY FLUORESCENCE ANALYSIS METHOD RÖNTGENFLUORESZENZ-ANALYSEVERFAHREN PROCÉDÉ D’ANALYSE PAR RAYONS X FLUORESCENTS (84) Designated Contracting States: • BURRELL, Anthony, K. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Los Alamos, NM 87544 (US) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR (74) Representative: Albrecht, Thomas Kraus & Weisert (30) Priority: 10.10.2006 US 850594 P Patent- und Rechtsanwälte Thomas-Wimmer-Ring 15 (43) Date of publication of application: 80539 München (DE) 05.08.2009 Bulletin 2009/32 (56) References cited: (60) Divisional application: JP-A- 2001 289 802 US-A1- 2003 027 129 12164870.3 US-A1- 2003 027 129 US-A1- 2004 004 183 US-A1- 2004 017 884 US-A1- 2004 017 884 (73) Proprietors: US-A1- 2004 093 526 US-A1- 2004 235 059 • Los Alamos National Security, LLC US-A1- 2004 235 059 US-A1- 2005 011 818 Los Alamos, NM 87545 (US) US-A1- 2005 011 818 US-B1- 6 329 209 • Caldera Pharmaceuticals, INC. US-B2- 6 719 147 Los Alamos, NM 87544 (US) • GOLDIN E M ET AL: "Quantitation of antibody (72) Inventors: binding to cell surface antigens by X-ray • BIRNBAUM, Eva, R.
    [Show full text]
  • SVM and a Novel POOL Method Coupled with THEMATICS For
    SVM and a Novel POOL Method Coupled with THEMATICS for Protein Active Site Prediction A DISSERTATION SUBMITTED TO THE COLLEGE OF COMPUTER AND INFORMATION SCIENCE OF NORTHEASTERN UNIVERSITY IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY By Wenxu Tong April 2008 ©Wenxu Tong, 2008 ALL RIGHTS RESERVED Acknowledgements I have a lot of people to thank. I am mostly indebted to my advisor Dr. Ron Williams. He generously allowed me to work on a problem with the idea he developed decades ago and guided me through the research to turn it from just a mere idea into a useful system to solve important problems. Without his kindness, wisdom and persistence, there would be no this dissertation. Another person I am so fortunate to meet and work with is Dr. Mary Jo Ondrechen, my co-advisor. It was her who developed the THEMATICS method, which this dissertation works on. Her guidance and help during my research is critical for me. I am grateful to all the committee members for reading and commenting my dissertation. Especially, I am thankful to Dr. Jay Aslam, who provided a lot of advice for my research, and Dr. Bob Futrelle, who brought me into the field and provided much help in my writing of this dissertation. I also thank Dr. Budil for the time he spent serving as my committee member, especially during all the difficulties and inconvenience he happened to experience unfortunately during the time. I am so fortunate to work in the THEMATICS group with Dr. Leo Murga, Dr.
    [Show full text]
  • Active Site of Chondroitin AC Lyase Revealed by the Structure Of
    Biochemistry 2001, 40, 2359-2372 2359 Active Site of Chondroitin AC Lyase Revealed by the Structure of Enzyme-Oligosaccharide Complexes and Mutagenesis†,‡ Weijun Huang,§ Lorena Boju,§ Lydia Tkalec,|,⊥ Hongsheng Su,|,# Hyun-Ok Yang,3 Nur Sibel Gunay,3 Robert J. Linhardt,3 Yeong Shik Kim,O Allan Matte,§ and Miroslaw Cygler*,§ Biotechnology Research Institute, 6100 Royalmount AVenue, Montre´al, Que´bec H4P 2R2 Canada, Montreal Joint Centre for Structural Biology, Montre´al, Que´bec, Canada, IBEX Technologies Inc., 5485 Pare Street, Montre´al, Que´bec H4P 1P7 Canada, Department of Chemistry, DiVision of Medicinal Chemistry and Department of Chemical and Biochemical Engineering, The UniVersity of Iowa, 115 South Grand AVenue, PHAR S328, Iowa City, Iowa 52242-1112, and Natural Products Research Institute, Seoul National UniVersity, Seoul 110-460, Korea ReceiVed October 17, 2000; ReVised Manuscript ReceiVed December 18, 2000 ABSTRACT: The crystal structures of FlaVobacterium heparinium chondroitin AC lyase (chondroitinase AC; EC 4.2.2.5) bound to dermatan sulfate hexasaccharide (DShexa), tetrasaccharide (DStetra), and hyaluronic acid tetrasaccharide (HAtetra) have been refined at 2.0, 2.0, and 2.1 Å resolution, respectively. The structure of the Tyr234Phe mutant of AC lyase bound to a chondroitin sulfate tetrasaccharide (CStetra) has also been determined to 2.3 Å resolution. For each of these complexes, four (DShexa and CStetra) or two (DStetra and HAtetra) ordered sugars are visible in electron density maps. The lyase AC DShexa and CStetra complexes reveal binding at four subsites, -2, -1, +1, and +2, within a narrow and shallow protein channel. We suggest that subsites -2 and -1 together represent the substrate recognition area, +1 is the catalytic subsite and +1 and +2 together represent the product release area.
    [Show full text]
  • 12) United States Patent (10
    US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S.
    [Show full text]
  • Structural and Biochemical Studies on Enzymes Involved in Natural Product Biosynthesis and Cellular Respiration by David S. Park
    STRUCTURAL AND BIOCHEMICAL STUDIES ON ENZYMES INVOLVED IN NATURAL PRODUCT BIOSYNTHESIS AND CELLULAR RESPIRATION BY DAVID S. PARK DISSERTATION Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biophysics and Computational Biology in the Graduate College of the University of Illinois at Urbana-Champaign, 2016 Urbana, Illinois Doctoral Committee: Professor Satish K. Nair, Chair, Director of Research Professor Robert Gennis Assistant Professor Hong Jin Professor Claudio Grosman ABSTRACT Natural products have recently become an interest in modern research. This is due to their synthesis mainly by living organisms and their natural biosynthesis and abundance. Many of these compounds have been found to have pharmaceutical and industrial applications, and have been used as the basis for derivatives that are already being used for large scale production. Despite initial availability, there now is an urgent need to isolate and produce new and more effective natural products. The good news is we are still continuing to discover new sources. Natural products will still be an important source for industrial and pharmaceutical development. One focus improving them is to understand the biosynthetic pathways of some of these natural products. Elucidating these biosynthetic pathways will allow us to be improve efficacy and allow for rational design of new and better compounds. The studies that were conducted in this dissertation focuses on structural studies of three enzymes involved with natural product synthesis. The most widely distributed component of brown algae is alginate, a cell wall polysaccharide composed of polymeric blocks of α-(1,4) O-linked β-D-mannuronate (M) and its C-5 epimer α-L- guluronate (G).
    [Show full text]
  • POLSKIE TOWARZYSTWO BIOCHEMICZNE Postępy Biochemii
    POLSKIE TOWARZYSTWO BIOCHEMICZNE Postępy Biochemii http://rcin.org.pl WSKAZÓWKI DLA AUTORÓW Kwartalnik „Postępy Biochemii” publikuje artykuły monograficzne omawiające wąskie tematy, oraz artykuły przeglądowe referujące szersze zagadnienia z biochemii i nauk pokrewnych. Artykuły pierwszego typu winny w sposób syntetyczny omawiać wybrany temat na podstawie możliwie pełnego piśmiennictwa z kilku ostatnich lat, a artykuły drugiego typu na podstawie piśmiennictwa z ostatnich dwu lat. Objętość takich artykułów nie powinna przekraczać 25 stron maszynopisu (nie licząc ilustracji i piśmiennictwa). Kwartalnik publikuje także artykuły typu minireviews, do 10 stron maszynopisu, z dziedziny zainteresowań autora, opracowane na podstawie najnow­ szego piśmiennictwa, wystarczającego dla zilustrowania problemu. Ponadto kwartalnik publikuje krótkie noty, do 5 stron maszynopisu, informujące o nowych, interesujących osiągnięciach biochemii i nauk pokrewnych, oraz noty przybliżające historię badań w zakresie różnych dziedzin biochemii. Przekazanie artykułu do Redakcji jest równoznaczne z oświadczeniem, że nadesłana praca nie była i nie będzie publikowana w innym czasopiśmie, jeżeli zostanie ogłoszona w „Postępach Biochemii”. Autorzy artykułu odpowiadają za prawidłowość i ścisłość podanych informacji. Autorów obowiązuje korekta autorska. Koszty zmian tekstu w korekcie (poza poprawieniem błędów drukarskich) ponoszą autorzy. Artykuły honoruje się według obowiązujących stawek. Autorzy otrzymują bezpłatnie 25 odbitek swego artykułu; zamówienia na dodatkowe odbitki (płatne) należy zgłosić pisemnie odsyłając pracę po korekcie autorskiej. Redakcja prosi autorów o przestrzeganie następujących wskazówek: Forma maszynopisu: maszynopis pracy i wszelkie załączniki należy nadsyłać w dwu egzem­ plarzach. Maszynopis powinien być napisany jednostronnie, z podwójną interlinią, z marginesem ok. 4 cm po lewej i ok. 1 cm po prawej stronie; nie może zawierać więcej niż 60 znaków w jednym wierszu nie więcej niż 30 wierszy na stronie zgodnie z Normą Polską.
    [Show full text]
  • An Unusual Substrate for Chondroitin AC Lyase
    Carbohydrate Research 338 (2003) 2101Á/2104 www.elsevier.com/locate/carres Chondroitin O-methyl ester: an unusual substrate for chondroitin AC lyase Fikri Y. Avci,a Toshihiko Toida,b Robert J. Linhardta,* a Department of Chemistry, Rensselaer Polytechnic Institute, Troy, NY 12180-3590, USA b Department of Bioanalytical Chemistry, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba 263-8522, Japan Received 27 May 2003; accepted 23 June 2003 Abstract Chondroitin O-methyl ester was depolymerized by chondroitin AC lyase (EC 4.2.2.5) from Flavobacterium heparinum. The major product isolated from the depolymerization reaction was found to be methyl a-L-threo-hex-4-enopyranosyluronate-(10/4)-2- acetamido-2-deoxy-a,b-D-galactopyranoside. # 2003 Elsevier Ltd. All rights reserved. Keywords: Chondroitin O-methyl ester; Chondroitin AC lyase; Flavobacterium heparinum 1. Introduction Chondroitin AC lyase (EC 4.2.2.5), from Flavobacterium heparinum, degrades chondroitin, chon- Chondroitins are linear, polydisperse, glycosaminogly- droitin 4-sulfate (CS-A), chondroitin 6-sulfate (CS-C), 3 cans (GAGs) with a repeating core of disaccharide and hyaluronic acid, 0/3)GlcpNAc(10/4)GlcAp(10/. structure comprised of a D-glucopyranosyluronic acid The mode of action for this enzyme has been established 3 Á5 (GlcAp)orL-idopyranosyluronic acid (IdoAp) glycosi- as random endolytic. Dermatan sulfate containing dically linked to 2-acetamido-2-deoxy-D-galactopyran- IdoAp has an inhibitory effect on chondroitin AC 6 ose (GalpNAc) residue. They are the major polysac- lyase. While there is no absolute requirement of a charide component of extracellular matrix proteogly- metal ion for chondroitin AC lyase activity, various cans.
    [Show full text]
  • The Hyaluronan Lyase of Streptococcus Pyogenes Bacteriophage H4489A John R
    Biochem. J. (2002) 365, 317–322 (Printed in Great Britain) 317 The hyaluronan lyase of Streptococcus pyogenes bacteriophage H4489A John R. BAKER1, Shengli DONG and David G. PRITCHARD Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, U.S.A. Many pathogenic streptococci produce extracellular hyaluronan shown to be a lyase with a distributive action pathway. Unlike lyases which are thought to aid the spread of the organism in most bacterial hyaluronidases that have been characterized, the host tissues. In addition, several phages of group A streptococci phage enzyme was found to specifically cleave hyaluronan, are known to synthesize a bound form of hyaluronidase. It has which adds credence to the view that its function is to digest the been suggested that the function of this hyaluronidase is to hyaluronan capsule of the host organism. This bacteriophage facilitate penetration of the hyaluronan capsule by phage and lyase may provide a practical alternative to the lyase from thus to gain access for the phage to the cell surface of the host Streptomyces hyalurolyticus as a reagent for the specific cleavage streptococcus [Hynes, Hancock and Ferretti (1995) Infect. of hyaluronan. Immun. 63, 3015–3020]. In the present work, the hyaluronidase of Streptococcus pyogenes bacteriophage H4489A, expressed in E. coli, has been purified and characterized. The enzyme was Key words: action pathway, hyaluronidase, substrate specificity. INTRODUCTION EXPERIMENTAL Materials and reagents Hyaluronan (HA) lyases are produced by many different genera of bacteria. In Gram-positive organisms, the HA lyase is often Plasmid pSF49, containing the hylP gene of S.
    [Show full text]
  • All Enzymes in BRENDA™ the Comprehensive Enzyme Information System
    All enzymes in BRENDA™ The Comprehensive Enzyme Information System http://www.brenda-enzymes.org/index.php4?page=information/all_enzymes.php4 1.1.1.1 alcohol dehydrogenase 1.1.1.B1 D-arabitol-phosphate dehydrogenase 1.1.1.2 alcohol dehydrogenase (NADP+) 1.1.1.B3 (S)-specific secondary alcohol dehydrogenase 1.1.1.3 homoserine dehydrogenase 1.1.1.B4 (R)-specific secondary alcohol dehydrogenase 1.1.1.4 (R,R)-butanediol dehydrogenase 1.1.1.5 acetoin dehydrogenase 1.1.1.B5 NADP-retinol dehydrogenase 1.1.1.6 glycerol dehydrogenase 1.1.1.7 propanediol-phosphate dehydrogenase 1.1.1.8 glycerol-3-phosphate dehydrogenase (NAD+) 1.1.1.9 D-xylulose reductase 1.1.1.10 L-xylulose reductase 1.1.1.11 D-arabinitol 4-dehydrogenase 1.1.1.12 L-arabinitol 4-dehydrogenase 1.1.1.13 L-arabinitol 2-dehydrogenase 1.1.1.14 L-iditol 2-dehydrogenase 1.1.1.15 D-iditol 2-dehydrogenase 1.1.1.16 galactitol 2-dehydrogenase 1.1.1.17 mannitol-1-phosphate 5-dehydrogenase 1.1.1.18 inositol 2-dehydrogenase 1.1.1.19 glucuronate reductase 1.1.1.20 glucuronolactone reductase 1.1.1.21 aldehyde reductase 1.1.1.22 UDP-glucose 6-dehydrogenase 1.1.1.23 histidinol dehydrogenase 1.1.1.24 quinate dehydrogenase 1.1.1.25 shikimate dehydrogenase 1.1.1.26 glyoxylate reductase 1.1.1.27 L-lactate dehydrogenase 1.1.1.28 D-lactate dehydrogenase 1.1.1.29 glycerate dehydrogenase 1.1.1.30 3-hydroxybutyrate dehydrogenase 1.1.1.31 3-hydroxyisobutyrate dehydrogenase 1.1.1.32 mevaldate reductase 1.1.1.33 mevaldate reductase (NADPH) 1.1.1.34 hydroxymethylglutaryl-CoA reductase (NADPH) 1.1.1.35 3-hydroxyacyl-CoA
    [Show full text]